LRRK2 and Parkinson disease: For instance, previous studies examining the absence of LBs in PD patients with leucine-rich repeat kinase 2 (LRRK2) mutations have often relied on a limited number of antibodies targeting the C-terminus of aSyn, potentially overlooking other proteoforms of aSyn130–139.